6.51

2.68% 0.17

After Hours: 6.51

Bausch Health Companies Inc (BHC)

Overview News Price History Option Chain Financials Why BHC Down? Discussions Forecast Stock Split Dividend History

Bausch Health Companies Inc stock is traded at $6.51, with a volume of 2.52M. It is up +2.68% in the last 24 hours and up +37.05% over the past month. Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.

Previous Close:

$6.34

Open:

$6.3

24h Volume:

2.52M

Relative Volume:

0.81

Market Cap:

$2.43B

Revenue:

$10.53B

Net Income/Loss:

$-1.23B

P/E Ratio:

-2.0055

EPS:

-3.246

Net Cash Flow:

$949.99M

1W Performance:

+4.16%

1M Performance:

+37.05%

6M Performance:

+8.68%

1Y Performance:

-13.32%

1-Day Range:

$6.18

$6.525

1-Week Range:

$6.05

$6.535

52-Week Range:

$4.33

$8.685

Bausch Health Companies Inc Stock (BHC) Company Profile

Name

Bausch Health Companies Inc

Sector

Healthcare (1080)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

514-744-6792

Address

2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC

Employee

20,300

Twitter

Next Earnings Date

2026-07-29

Latest SEC Filings

BHC's Discussions on Twitter

Compare BHC vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BHC Bausch Health Companies Inc	6.51	2.32B	10.53B	-1.23B	949.99M	-3.246
TAK Takeda Pharmaceutical Co Adr	17.63	55.60B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.77	42.81B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.70	43.16B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	73.79	30.39B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	499.73	21.95B	3.17B	1.29B	1.01B	27.09

Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Equal Weight
Aug-02-24	Downgrade	Piper Sandler	Neutral → Underweight
Jul-10-24	Initiated	Raymond James	Mkt Perform
Sep-20-23	Upgrade	Jefferies	Hold → Buy
Jun-16-23	Downgrade	TD Cowen	Outperform → Market Perform
Jul-29-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-29-22	Downgrade	Truist	Buy → Hold
Jul-28-22	Downgrade	JP Morgan	Overweight → Neutral
Jun-13-22	Resumed	JP Morgan	Overweight
Mar-24-21	Downgrade	BofA Securities	Neutral → Underperform
Feb-17-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jan-22-21	Downgrade	Piper Sandler	Overweight → Neutral
Sep-17-20	Upgrade	BofA Securities	Underperform → Neutral
Aug-24-20	Reiterated	H.C. Wainwright	Buy
Jun-17-20	Reiterated	H.C. Wainwright	Buy
Apr-24-20	Initiated	Citigroup	Buy
Apr-02-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-29-20	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-22-20	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-12-19	Upgrade	JP Morgan	Neutral → Overweight
Dec-02-19	Initiated	Goldman	Neutral
Oct-25-19	Initiated	Cowen	Outperform
Sep-12-19	Initiated	Guggenheim	Buy
Aug-15-19	Upgrade	TD Securities	Hold → Buy
Jul-19-19	Initiated	Wolfe Research	Outperform
Jun-11-19	Resumed	Barclays	Overweight
May-13-19	Upgrade	JP Morgan	Underweight → Neutral
Mar-20-19	Initiated	SunTrust	Buy
Jan-02-19	Upgrade	Piper Jaffray	Neutral → Overweight
Nov-05-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-13-18	Upgrade	Piper Jaffray	Underweight → Neutral

View All

Bausch Health Companies Inc Stock (BHC) Latest News

Aug 14, 2026

Bausch Health Companies Inc.: Target Price Consensus and Analysts Recommendations | BVF | CA0717341071 - marketscreener.com

Aug 14, 2026

Bausch Health Stock Gains Momentum as Stronger Earnings, Raised Outlook and Debt Progress Lift Investor Optimism - kalkine.ca

Aug 14, 2026

Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month - AOL.com

Aug 14, 2026

Aug 13, 2026

Bausch Health Stock Faces Renewed Pressure as Investor Confidence Weakens - kalkine.ca

Aug 13, 2026

Aug 12, 2026

Bausch Health: Q2 Beat And Cheap, But Debt Overhang Remains Substantial (NYSE:BHC) - Seeking Alpha

Aug 12, 2026

BHC Stock Price Prediction 2025-2026 | Bausch Health Companies Inc Forecast - 24/7 Wall St.

Aug 12, 2026

What Is Fuelling Bausch Health (TSX:BHC) Midcap Interest? - Kalkine Media

Aug 12, 2026

Is Bausch Health (TSX:BHC) Finding Sustainable Pharma Momentum? - kalkinemedia.com

Aug 12, 2026

Bausch Health Stock Faces Renewed Pressure as -1.70% Decline Signals Cautious Investor Sentiment - kalkine.ca

Aug 12, 2026

Bausch Health jumps 40% post-Q2 on strong earni... - Pluang

Aug 12, 2026

Aug 11, 2026

Bausch Health Stock Climbs 1.49% as Pharmaceutical Portfolio Strength and Debt Reduction Efforts Boost Investor Confidence - kalkine.ca

Aug 11, 2026

Aug 10, 2026

Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month - The Motley Fool

Aug 10, 2026

Bausch Health (BHC) Q2 2026 Earnings Call Transcript - AOL.com

Aug 10, 2026

Bausch + Lomb Updates Board, Reaffirms 2026 Guidance - VisionMonday.com

Aug 10, 2026

Aug 08, 2026

Dimensional Fund Advisors LP Raises Position in Bausch Health Cos Inc. $BHC - marketbeat.com

Aug 08, 2026

Aug 06, 2026

Bausch Health CEO joins Bausch + Lomb board of directors By Investing.com - Investing.com South Africa

Aug 06, 2026

Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance - BioSpace

Aug 06, 2026

Bausch Health CEO joins Bausch + Lomb board of directors - Investing.com

Aug 06, 2026

Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board - PR Newswire

Aug 06, 2026

Bausch Health requests four new Bausch + Lomb directors with about 87% stake - Stock Titan

Aug 06, 2026

Aug 04, 2026